Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Schizophr Res ; 86(1-3): 234-43, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16887334

ABSTRACT

Few studies have assessed the comparative efficacy and safety of atypical and typical antipsychotic medications in patients within their first episode of psychosis. This study examined the effectiveness of the atypical antipsychotic olanzapine and the typical antipsychotic haloperidol in patients experiencing their first episode of a schizophrenia-related psychotic disorder over a 2-year treatment period. Two hundred and sixty-three patients were randomized to olanzapine or haloperidol in a doubleblind, multisite, international 2-year study. Clinical symptoms and side effects were assessed at baseline and longitudinally following randomization for the duration of the study. Olanzapine and haloperidol treatment were both associated with substantial and comparable reductions in symptom severity (the primary outcome measure) over the course of the study. However, the treatment groups differed on two secondary efficacy measures. Patients were less likely to discontinue treatment with olanzapine than with haloperidol: mean time (in days) in the study was significantly greater for those treated with olanzapine compared to haloperidol (322.09 vs. 230.38, p<0.0085). Moreover, remission rates were greater in patients treated with olanzapine as compared to those treated with haloperidol (57.25% vs. 43.94%, p<0.036). While extrapyramidal side effects were greater in those treated with haloperidol, weight gain, cholesterol level and liver function values were greater in patients treated with olanzapine. The data from this study suggest some clinical benefits for olanzapine as compared to haloperidol in first episode patients, which must be weighed against those adverse effects that are more likely with olanzapine.


Subject(s)
Antipsychotic Agents/therapeutic use , Haloperidol/therapeutic use , Psychotic Disorders/drug therapy , Adult , Antipsychotic Agents/adverse effects , Benzodiazepines/adverse effects , Benzodiazepines/therapeutic use , Double-Blind Method , Female , Follow-Up Studies , Haloperidol/adverse effects , Humans , International Cooperation , Male , Neuropsychological Tests , Olanzapine , Psychiatric Status Rating Scales/statistics & numerical data , Treatment Outcome
2.
J Clin Psychiatry ; 62(4): 273-81, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11379842

ABSTRACT

BACKGROUND: Olanzapine has demonstrated efficacy in the treatment of acute mania in 2 double-blind, placebo-controlled trials. We describe the results of the open-label extension from one of these trials. METHOD: In a 3-week, double-blind study of patients with DSM-IV bipolar I disorder, olanzapine was superior to placebo for the treatment of acute manic symptoms. Of the 139 patients who entered the double-blind phase of the 3-week study, 113 patients continued into the 49-week open-label extension. Efficacy measurements including the Young Mania Rating Scale (YMRS), the 21-item Hamilton Rating Scale for Depression (HAM-D-21), the Clinical Global Impressions scale-Bipolar Version, and the Positive and Negative Syndrome Scale and safety measurements including the Simpson-Angus scale, the Barnes Akathisia Scale, and the Abnormal Involuntary Movement Scale were completed throughout. The analysis considered all treatment results, starting with the first olanzapine dose. Adjunctive lithium and fluoxetine were allowed during the open-label extension. RESULTS: The mean length of olanzapine treatment was 6.6 months, with a mean modal dose of 13.9 mg/day. A significant mean improvement in the YMRS total score, baseline to endpoint (-18.01, p < .001), was observed. During treatment, 88.3% of patients experienced a remission of manic symptoms (YMRS total score < or =12), and only 25.5% subsequently relapsed (YMRS total score > or = 15). Significant improvement in HAM-D-21 scores was observed (p < .001). Forty-one percent of patients were maintained on olanzapine monotherapy. The most common treatment-emergent adverse events reported were somnolence (46.0%), depression (38.9%), and weight gain (36.3%). CONCLUSION: During up to 1 year of olanzapine therapy, either as monotherapy or in combination with lithium and/or fluoxetine, patients with bipolar disorder demonstrated significant improvement in mania and depression symptoms with a favorable safety profile. Further double-blind, controlled studies are needed to confirm these results.


Subject(s)
Antipsychotic Agents/therapeutic use , Bipolar Disorder/drug therapy , Pirenzepine/analogs & derivatives , Pirenzepine/therapeutic use , Adult , Antipsychotic Agents/administration & dosage , Antipsychotic Agents/adverse effects , Benzodiazepines , Bipolar Disorder/diagnosis , Bipolar Disorder/psychology , Depressive Disorder/chemically induced , Double-Blind Method , Drug Administration Schedule , Drug Therapy, Combination , Female , Fluoxetine/therapeutic use , Humans , Lithium/therapeutic use , Male , Middle Aged , Olanzapine , Pirenzepine/administration & dosage , Pirenzepine/adverse effects , Placebos , Psychiatric Status Rating Scales/statistics & numerical data , Severity of Illness Index , Sleep/drug effects , Treatment Outcome , Weight Gain/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...